Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fulvestrant + Zenocutuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fulvestrant||Faslodex||ICI 182,780||Hormone - Anti-estrogens 18||Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).|
|Zenocutuzumab||MCLA-128|MCLA128|MCLA 128||HER2 (ERBB2) Antibody 53 HER3 (ERBB3) Antibody 17||Zenocutuzumab (MCLA-128) is a bispecific antibody that targets Erbb2 (Her2) and Erbb3, resulting in antibody-dependent cell-mediated cytotoxicity against tumor cells (Cancer Res 2016;76(14 Suppl):Abstract nr CT050, PMID: 32054397).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03321981||Phase II||Letrozole + Zenocutuzumab Anastrozole + Zenocutuzumab Fulvestrant + Zenocutuzumab Exemestane + Zenocutuzumab Trastuzumab + Zenocutuzumab Trastuzumab + Vinorelbine + Zenocutuzumab||MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer||Active, not recruiting||USA||6|